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Abstract
One of the major causes of chemotherapy failure in cancer treatment is multidrug resistance (MDR) which is mediated by
the ABCB1/P-glycoprotein. Previously, through the use of an extensive screening process, we found that vardenafil, a
phosphodiesterase 5 (PDE-5) inhibitor significantly reverses MDR in ABCB1 overexpressing cancer cells, and its efficacy was
greater than that of tadalafil, another PDE-5 inhibitor. The present study was designed to determine the reversal
mechanisms of vardenafil and tadalafil on ABC transporters-mediated MDR. Vardenafil or tadalafil alone, at concentrations
up to 20 mM, had no significant toxic effects on any of the cell lines used in this study, regardless of their membrane
transporter status. However, vardenafil when used in combination with anticancer substrates of ABCB1, significantly
potentiated their cytotoxicity in ABCB1 overexpressing cells in a concentration-dependent manner, and this effect was
greater than that of tadalafil. The sensitivity of the parenteral cell lines to cytotoxic anticancer drugs was not significantly
altered by vardenafil. The differential effects of vardenafil and tadalafil appear to be specific for the ABCB1 transporter as
both vardenafil and tadalafil had no significant effect on the reversal of drug resistance conferred by ABCC1 (MRP1) and
ABCG2 (BCRP) transporters. Vardenafil significantly increased the intracellular accumulation of [
3H]-paclitaxel in the ABCB1
overexpressing KB-C2 cells. In addition, vardenafil significantly stimulated the ATPase activity of ABCB1 and inhibited the
photolabeling of ABCB1 with [
125I]-IAAP. Furthermore, Western blot analysis indicated the incubation of cells with either
vardenafil or tadalafil for 72 h did not alter ABCB1 protein expression. Overall, our results suggest that vardenafil reverses
ABCB1-mediated MDR by directly blocking the drug efflux function of ABCB1.
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Introduction
The resistance of tumor cells to a variety of structurally and
mechanistically unrelated cytotoxic drugs, also known as multi-
drug resistance (MDR), is one of the major obstacles in the
successful treatment of cancer [1]. It is estimated that approxi-
mately 500,000 new cases of cancer each year exhibit the drug
resistant phenotype [2]. One of the known causes of MDR is
overexpression of the ATP-binding cassette (ABC) transporters,
such as P-glycoprotein (ABCB1/P-gp), multidrug resistance
proteins (ABCCs/MRPs) and breast cancer resistant protein
(ABCG2/BCRP). These transporters actively efflux a variety of
structurally and functionally diverse chemotherapeutic drugs out
of cancer cells, thereby reducing the intracellular drug accumu-
lation, increasing the likelihood of decreased cytotoxic and thus
unsuccessful treatment [3,4,5,6]. Currently, 48 distinct ABC
transporters have been identified in the human genome, and
these can further divided into seven subfamilies (A–G) based on
sequence similarities [3]. Among these transporters, the ABCB1
transporter is the most important mediator of MDR [7,8], and is
responsible for chemotherapeutic drug resistance to a variety of
drug, including vinca alkaloids, anthracyclines, epipodophyllotox-
ins and taxanes [9]. The overexpression of ABCB1 occurs in 40–
50% of cancer patients [10], and is associated with a poor clinical
outcome [11,12]. Based on these findings, a number of studies
have attempted to selectively inhibit ABCB1 activity as a strategy
to reverse MDR in cancer chemotherapy. Indeed, in the past 30
years, significant efforts have been made to design and test specific
ABCB1 inhibitors and this has resulted in the development of
three generations of ABCB1 inhibitors. However, currently, none
of the compounds in the three generations have been approved for
clinical use. The first-generation ABCB1 inhibitors, including
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produced undesirable adverse effects at plasma concentrations
necessary to inhibit ABCB1 [13]. The second-generation ABCB1
inhibitors, such as valspodar/PSC-833 and biricodar/VX-710,
had improved tolerability compared to the first-generation
compounds. However, they produced unpredictable interactions
with other transport proteins and inhibited CYP3A4, one of the
major chemotherapeutic drug metabolizing enzymes, thereby
reducing the the clearance and metabolism of chemotherapeutic
drugs [14]. The third-generation inhibitors were more selective for
the ABCB1 transporters in ongoing clinical trials. Nonetheless,
some of these compounds produced significant adverse effects and
had an unfavorable pharmacokinetic profile, including poor
solubility as well as reducing the clearance of clinically used
anticancer drugs [15]. Recent results from our laboratory and
others indicate that several tyrosine kinase inhibitors (TKIs),
including imatinib [16], nilotinib [17], lapatinib [18], and erlotinib
[19], can reverse MDR to antineoplastic drugs mediated by ABC-
transporters. However, the reversal potential of these TKIs have
not been determined in clinical trials. Consequently, it is necessary
to develop more efficacious, non-toxic and less expensive
compounds to reverse MDR in cancer cells. In the course of our
search for compounds that reverse MDR, we found that vardenafil
and tadalafil, two phosphodiesterase type-5 (PDE-5) inhibitors
clinically used in the treatment of male erectile dysfunction,
significantly reversed ABCB1-mediated MDR. In the present
study, we conducted experiments to ascertain the reversal
mechanism of vardenafil and tadalafil in ABCB1 overexpressing
cancer cells. In addition, we also examined their effect on other
major ABC drug transporters such as MRP1 and BCRP.
Materials and Methods
Reagents
Vardenafil and tadalafil were purchased from Toronto
Research Chemicals Inc. (Ontario, Canada). [
3H]-paclitaxel
(37.9 Ci/mmol) was purchased from Moravek Biochemicals Inc
(Brea, CA). [
125I]-Iodoarylazidoprazosin (IAAP) (2,200 Ci/mmol)
was obtained from Perkin Elmer Life Sciences (Boston, MA).
Monoclonal antibody C-219 (against ABCB1) was acquired from
Signet Laboratories Inc. (Dedham, MA). Anti-glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) monoclonal antibody
(14C10) was obtained from Cell Signaling Technology, Inc.
(Danvers, MA). Fumitremorgin C (FTC) was synthesized by
Thomas McCloud Developmental Therapeutics Program, Natural
Products Extraction Laboratory, NCI, NIH (Bethesda, MD).
ONO1078 was a gift from Dr. Akiyama (Kagoshima University,
Japan). Paclitaxel, vincrinstine (VCR), colchicine, 7-ethyl-10-
hydroxy-20 (S)-camptothecin (SN-38), verapamil, dimethyl sulf-
oxide (DMSO), 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan
(MTT) and all other chemicals were purchased from Sigma
Chemical Co. (St. Louis, MO).
Cell lines and cell culture
The ABCB1/P-gp-overexpressing drug-resistant cell line KB-
C2 was established in a cell culture medium by a step-wise
selection of the parental human epidermoid carcinoma cell line
KB-3-1 using colchicine at concentrations up to 2 mg/ml [20].
The KB-C2 and KB-3-1 were kindly provided by Dr Shin-ichi
Akiyama (Kagoshima University, Japan). HEK293-pcDNA3.1
and wild-type HEK/ABCG2 transfected cells were established by
selection with G418 after transfecting HEK293 with either empty
pcDNA3.1 vector or pcDNA3.1 vector containing full length of
ABCG2 coding arginine (R) at 482 amino acid position,
respectively, and were then cultured in a medium with 2 mg/ml
of G418 [21]. Similarly, the HEK/MRP1 (ABCC1) and HEK/
ABCB1 cells were generated by transfecting the HEK293 with the
MRP1 expression vector and the ABCB1 expressing vector,
respectively [22]. All of the cell lines were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10%
bovine serum, 100 units/ml penicillin, and 100 mg/ml strepto-
mycin in a humidified incubator containing 5% CO2 at 37uC.
Cell cytotoxicity by MTT assay
The MTT assay was used to assess cytotoxicity. The cultured
cells were harvested with trypsin and resuspended in a final
concentration of 4610
3 cells/well for KB-3-1, 7.5610
3 cells/well
for KB-C2 and 8610
3 for all of the other cell lines used in this
study. Cells were seeded evenly in 96 well multiplates. In the
reversal experiments, different concentrations of chemotherapeu-
tic drugs (20 ml/well) were added into designated wells after 1 h
with or without exposure to potential reversal compounds
vardenafil, tadalafil, verapamil, ONO-1078, or FTC (20 ml/well).
After 68 h of incubation, 20 ml of the MTT solution (4 mg/ml)
was added to each well, and the plate was further incubated for
4 h at 37uC, allowing viable cells to convert the yellow-colored
MTT into dark-blue formazan crystals. Subsequently, the medium
was discarded, and 100 ml of DMSO was added into each well to
dissolve the formazan crystals generating purple color. The
absorbance was determined at 570 nm by an OPSYS Microplate
Reader from DYNEX Technologies, Inc. (Chantilly, VA). The
degree of resistance was calculated by dividing the IC50
(concentrations required to inhibit growth by 50%) for the
resistant cells by that of the parental sensitive cells. The degree
of the reversal of MDR was calculated by dividing the IC50 for
cells with the anticancer drug in the presence or absence of
reversal agents by that of parental cells with anticancer drugs
obtained in the absence of reversal agent. The IC50 values were
calculated from survival curves using the Bliss method.
[
3H]-paclitaxel accumulation and efflux
The intracellular accumulation of [
3H]-paclitaxel was measured
as previously described [23]. Briefly, confluent cells in 24-well
plates were preincubated with or without the reversing agents for
1 h at 37uC. Intracellular paclitaxel accumulation was measured
by incubating cells with 0.1 mM[
3H]-paclitaxel for 2 h in the
presence or absence of the reversing agents at 37uC. The cells were
washed three times with ice-cold PBS, then suspended in fresh
medium with or without reversing agents at 37uC. Aliquots of the
extracellular medium (40 ml) were collected at various time points
(0, 60, 120 min) and finally the cells were collected and lysed in
10 mM lysis buffer (pH 7.4, containing 1% Triton X-100 and
0.2% SDS). Each sample was placed in scintillation fluid and the
radioactivity was measured in a Packard TRI-CARB1 1900CA
liquid scintillation analyzer from Packard Instrument Company,
Inc. (Downers Grove, IL).
Western blot and immunofluorescence analysis
To determine the effect of vardenafil or tadalafil on the
expression of ABCB1, KB-C2 cells were incubated with 10 mM
vardenafil or tadalafil for 0, 36 and 72 h. Following incubation,
the cells were harvested and rinsed twice with ice-cold PBS and
total cell lysates were collected with cell lysis buffer (16PBS, 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 100 mg/ml
phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin, 10 mg/ml
leupeptin) for 30 min with gentle rocking and clarified by
centrifugation at 12,000 rpm for 10 min at 4uC. Equal amounts
(100 mg of protein) of cell lysates were resolved by sodium dodecyl
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electrophoretically transferred onto polyvinylidene fluoride
(PVDF) membranes. After incubation in a blocking solution
containing 5% non-fat milk in TBST buffer (10 mM Tris-HCL
(pH 8.0), 150 mM NaCl, and 0.1% Tween 20) for 1 h at room
temperature, membranes were immunoblotted overnight with
primary monoclonal antibodies C219 (1:200) against ABCB1 or
14C10 (1:200) against GAPDH at 4uC. Subsequently, the
membranes were washed three times for 15 min with TBST
buffer and incubated at room temperature for 2 h with HRP-
conjugated secondary antibody at 1:1000 dilutions. The mem-
branes underwent three additional washes for 15 min with TBST
buffer and the protein-antibody complex were visualized by the
enhanced Phototope TM-HRP Detection Kit (Cell Signaling,
USA) and exposed to Kodak medical X-ray processor (Kodak,
USA) [18]. For the immunofluorescence analysis, cells (2610
3)
were seeded in 24 well plates and vardenafil or tadalafil at 10 mM
were added into the wells after 12 h of incubation at 37uCi na
humidified atmosphere of 5% CO2. After incubation for 72 h of
incubation, cells were washed with PBS and fixed with 4%
paraformaldehyde for 15 min at room temperature and then
rinsed with PBS three times. A monoclonal antibody C219 against
ABCB1 (1:500) (Signet Laboratories Inc., Dedham, MA) was
added and incubated overnight and Alexa flour 488 goat
antimouse IgG (1:1000, Molecular Probe, Carlsbad, CA) was
added and cultured for 1 h. Propidium iodide was used for nuclear
counterstaining.
ATPase assay of ABCB1
The Vi-sensitive ATPase activity of ABCB1 in membrane
vesicles of High-Five insect cells was measured as previously
described [24]. Briefly, the membrane vesicles (10 mg of protein)
were incubated in ATPase assay buffer (50 mM MES [pH 6.8],
50 mM KCl, 5 mM sodium azide, 2 mM EGTA, 2 mM
dithiothreitol, 1 mM ouabain and 10 mM MgCl2) with or without
0.3 mM orthovanadate (freshly prepared) at 37uC for 5 min, then
incubated with different concentrations of drug at 37uC for 3 min.
The ATPase reaction was started by the addition of 5 mM ATP,
and the total volume was 0.1 ml. After incubation at 37uC for
20 min, the reactions were stopped by the addition of 0.1 ml of
5% SDS solution and vortexed and kept at room temperature.
The liberated Pi was measured as previously described [24].
Photoaffinity labeling of ABCB1 with [
125I]-IAAP
The photoaffinity labeling of ABCB1 with [
125I]-IAAP was
performed as previously described [25]. The membrane vesicles
from High-Five insect cells expressing ABCB1 (50 mg of protein)
were incubated at room temperature with different concentrations
of drugs in the ATPase assay buffer with [
125I]-IAAP (7 nM) for
5 min under subdued light. The samples were photo cross-linked
by using a 365 nm UV light source for 10 min at room
temperature. After the samples were placed in an SDS-PAGE in
a 7% Tris-acetate NuPAGE gel, the gels were dried and exposed
to Bio-Max MR film (Eastman Kodak Co., NY, USA) at 270uC
for 8–12 h. The radioactivity incorporated into the ABCB1 band
was quantified using the STORM 860 PhosphorImager system
and ImageQuaNT (Molecular Dynamics, CA).
Ligand-ABCB1 structure preparation
Vardenafil, tadalafil (modeled as R,R isomer) and IAAP were
constructed using the fragment dictionary of Maestro 9.0 and the
energy minimized by Macromodel program v9.7 (Schro ¨dinger,
Inc., New York, NY, 2009) using the OPLSAA force field [26]
with the steepest descent followed by truncated Newton conjugate
gradient protocol. Partial atomic charges were computed using the
OPLS-AA force field. The low-energy 3D structures of vardenafil,
tadalafil and IAAP were generated with the following parameters
present in LigPrep v2.3: different protonation states at physiolog-
ical pH, all possible tautomers and ring conformations.
Protein structure preparation
The X-ray crystal structure of ABCB1 in the apoprotein state
(PDB ID: 3G5U) and in complex with inhibitors QZ59-RRR (PDB
ID: 3G6O) and QZ59-SSS (PDB ID: 3G61) was obtained from the
RCSB Protein Data Bank and were used to build the homology
model of human ABCB1 [27]. The homology modeling was
conducted using the default parameters of Prime v2.1 as
implemented in Maestro 9.0. The input file for the amino acid
sequence of human ABCB1 in the Prime structure prediction
application was obtained as fasta file (uniprot accession number
P08183.3) extracted from http://www.uniprot.org. The co-crystal
structures of ABCB1 from the mouse model in complex with
QZ59-RRR and QZ59-SSS inhibitors were used as templates for
modeling site-1 and site-2, respectively; while apoprotein-ABCB1
was used as a template for modeling the site-3 and site-4. The
resultant alignment of human ABCB1 and mouse ABCB1
sequences produced 87% sequence identity and 93% similarity.
Based on the resultant alignment that was constructed using
default parameters, the side chains were optimized and residues
were minimized. The initial structure thus obtained was refined by
means of default parameters mentioned in protein preparation
facility implemented in Maestro v9.0 and Impact program v5.5
(Schro ¨dinger, Inc., New York, NY, 2009), in which the
protonation states of residues were adjusted to the dominant ionic
forms at pH 7.4. Refined human ABCB1 homology model was
further used to generate four different receptor grids by selecting
QZ59-RRR (site-1) and QZ59-SSS (site-2) bound ligands, all amino
acid residues known to contribute to verapamil binding (site-3) and
two residues known to be common to three previous sites (site-4) as
shown in Table S1.
Docking protocol
The docking calculations were performed using the ‘‘Extra
Precision’’ (XP) mode of Glide program v5.5 (Schro ¨dinger, Inc.,
New York, NY, 2009) and the default parameters. The top scoring
pose-ABCB1 complex was then subjected to energy minimization
using Macromodel program v9.7 using the OPLS-AA force field
[26] and used for graphical analysis. All computations were
carried out on a Dell Precision 470 n dual processor with the
Linux OS (Red Hat Enterprise WS 4.0).
Statistical Analysis
All experiments were repeated at least three times and the
differences were determined by using the Student’s t-test. The
statistical significance was determined at p,0.05.
Results
Vardenafil significantly enhances the drug sensitivity of
ABCB1 overexpressing cancer cells but does not alter the
drug sensitivity in ABCC1 and ABCG2 overexpressing
cells
Prior to determining if MDR could be reversed by vardenafil or
tadalafil, we first determined their cytotoxic effects in different cell
lines using the MTT assay. The results indicated that both
vardenafil and tadalafil did not inhibit the growth of any of the cell
lines used in this study at concentrations up to 20 mM (data not
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PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e19329shown). We then determined the effect of vardenafil or tadalafil
on the sensitivity of anticancer drugs in ABCB1-, ABCC1-, and
ABCG2-overexpressing MDR cells. As shown in Table 1,
vardenafil at 5 and 10 mM, produced a concentration-dependent
increase in the cytotoxicity of colchicine and paclitaxel in
ABCB1-overexpressing KB-C2 cells. Similarly, vardenafil in-
creased the sensitivity of ABCB1 transfected HEK/ABCB1 cells
to vincristine and paclitaxel (Table 2). In contrast, vardenafil did
not significantly alter the cytotoxicity of the tested drugs in the
parental sensitive KB-3-1 cells (Table 1). In addition, vardenafil
did not reverse MDR induced by cells expressing ABCC1 and
ABCG2 (Table S2) or significantly alter the IC50 values of
cisplatin, which is not a substrate of ABCB1 (Table 1 and 2). We
also determined if MDR could be reversed by tadalafil, another
PDE-5 inhibitor. The results indicated that tadalafil, at
concentrations of 5 or 10 mM also significantly enhanced the
colchicine and paclitaxel sensitivity in KB-C2 cells and
the vincristine and paclitaxel in HEK/ABCB1 cells. However,
the fold reversal was significantly less than that of vardenafil.
(Table 1 and 2).
Vardenafil significantly increases the accumulation of
intracellular paclitaxel in ABCB1-overexpressing cells by
inhibiting drug efflux
In order to determine vardenafil’s reversal mechanism for the
ABCB1 transporter, we measured the accumulation of the [
3H]-
paclitaxel in the absence and presence of vardenafil. As shown in
Figure 1 A, the intracellular concentration of paclitaxel in KB-C2
cells was approximately 55% of that in the parental KB-3-1 cells.
However, 10 mM of vardenafil significantly increased the
intracellular accumulation of [
3H]-paclitaxel in KB-C2 by 1.6-
fold without altering the levels accumulated in KB-3-1 cells
(Figure 1 A). In contrast, although tadalafil at 10 mM had
significant effect on the paclitaxel accumulation, the accumula-
tion was much less than that of vardenafil and positive control
verapamil at 10 mM.
In another series of experiments, we determined the effect of
vardenafil on paclitaxel efflux. The intracellular levels of paclitaxel
were measured over a period of 2 h (Figure 1B). As expected, a
significantly higher concentration of paclitaxel was effluxed from
the KB-C2 cells compared to KB-3-1 cells, and the amount of
effluxed paclitaxel increased with time. At the one hour time point,
70% of the accumulated paclitaxel was effluxed from the KB-C2
cells in the absence of vardenifil, where as 10 mM of significantly
blocked the efflux function of ABCB1, with 75% of the paclitaxel
being retained inside the KB-C2 cells (Figure 1B). There was no
significant change in the concentration of paclitaxel subjected to
efflux in parental KB-3-1 cells in the absence or presence of
vardenafil. Thus, vardenifil significantly inhibited paclitaxel efflux
from the KB-C2 cells to the extent that efflux from this cell line
was comparable to that of the control cells (Figure 1B).
Table 1. The effect of vardenafil and tadalafil on the reversal
of ABCB1-mediated resistance to colchicine, paclitaxel and
cisplatin in drug selected cell line.
Compounds IC50 ± SD (mM) (fold reversal)
KB-3-1 KB-C2 (ABCB1)
Colchicine 0.006360.0013 (1.00) 2.901760.6127 (1.00)
+Vardenafil 5 mM 0.007060.0014 (0.90) 0.105360.0215** (27.6)
+Vardenafil 10 mM 0.006860.0012 (0.93) 0.015760.0063** (184.8)
+Tadalafil 5 mM 0.007360.0009 (0.86) 0.692360.1518** (4.19)
+Tadalafil 10 mM 0.007160.0015 (0.89) 0.454760.1033** (6.38)
+Verapamil 10 mM 0.006460.0011 (0.98) 0.034760.0071** (83.6)
Paclitaxel 0.006660.0016 (1.00) 0.735460.0141 (1.00)
+Vardenafil 5 mM 0.007460.0015 (0.89) 0.028160.0067** (26.2)
+Vardenafil 10 mM 0.007260.0017 (0.92) 0.013660.0025** (54.1)
+Tadalafil 5 mM 0.007160.0020 (0.93) 0.291160.0669** (2.53)
+Tadalafil 10 mM 0.006560.0028 (1.02) 0.164160.0311** (4.48)
+Verapamil 10 mM 0.006060.0009 (1.10) 0.013260.0035** (55.7)
Cisplatin 1.903260.0709 (1.00) 1.787760.2171 (1.00)
+Vardenafil 5 mM 2.131660.3653 (0.89) 2.055560.7811 (0.87)
+Vardenafil 10 mM 2.036460.6313 (0.93) 1.865160.5409 (0.96)
+Tadalafil 5 mM 1.989960.4975 (0.96) 1.770060.7257 (1.01)
+Tadalafil 10 mM 1.789060.6083 (1.06) 1.922160.9034 (0.93)
+Verapamil 10 mM 1.870360.2330 (1.02) 1.789060.6472 (1.00)
Cell survival was determined by MTT assay as described in ‘‘Materials and
Methods’’. Data are expressed as the means 6 SD of at least three independent
experiments performed in triplicate. The magnitude of the fold-reversal of MDR
fold reversal (values given in parentheses) was calculated by dividing the IC50
for cells with the anticancer drug in the absence of inhibitor by that obtained in
the presence of inhibitor.
**represents P,0.01, for values versus that obtained in the absence of inhibitor.
doi:10.1371/journal.pone.0019329.t001
Table 2. The effect of vardenafil and tadalafil on the reversal
of ABCB1-mediated resistance to vincristine, paclitaxel and
cisplatin in ABCB1 transfected cell line.
Compounds IC50 ± SD (mM) (fold reversal)
HEK293/pcDNA3.1 HEK/ABCB1 (ABCB1)
Vincristine 11.5561.59 (1.00) 169.84612.93 (1.00)
+Vardenafil 5 mM 13.1360.93 (0.88) 41.4166.12** (4.10)
+Vardenafil 10 mM 9.7262.13 (1.19) 14.6462.36** (11.60)
+Tadalafil 5 mM 10.0261.24 (1.15) 112.9465.04 (1.50)
+Tadalafil 10 mM 8.5760.62 (1.35) 69.2763.48* (2.45)
+Verapamil 10 mM 8.2361.11 (1.40) 18.2164.82** (9.33)
Paclitaxel 23.7365.21 (1.00) 219.14613.16 (1.00)
+Vardenafil 5 mM 21.8562.04 (1.09) 56.8367.74** (3.86)
+Vardenafil 10 mM 20.0963.06 (1.18) 25.2364.17** (8.69)
+Tadalafil 5 mM 24.0462.95 (0.99) 159.78611.52 (1.37)
+Tadalafil 10 mM 19.6463.17 (1.21) 96.9264.83* (2.26)
+Verapamil 10 mM 20.1762.52 (1.18) 31.0362.19** (7.06)
Cisplatin 890.32633.92 (1.00) 850.84682.53 (1.00)
+Vardenafil 5 mM 839.03648.37 (1.06) 893.19632.60 (0.95)
+Vardenafil 10 mM 892.44619.26 (1.00) 782.82659.31 (1.09)
+Tadalafil 5 mM 901.29667.23 (0.99) 909.06698.44 (0.94)
+Tadalafil 10 mM 792.85692.60 (1.12) 783.60684.20 (1.09)
+Verapamil 10 mM 853.62661.04 (1.04) 725.71648.56 (1.17)
Cell survival was determined by MTT assay as described in ‘‘Materials and
Methods’’. Data are expressed as the means 6 SD of at least three independent
experiments performed in triplicate. The fold-The magnitude of the MDR fold
reversalreversal of MDR ((values given in parentheses) was calculated by
dividing the IC50 for cells with the anticancer drug in the absence of inhibitor by
that obtained in the presence of inhibitor.
**represents P,0.01,
*represents P,0.05, for values versus that obtained in the absence of inhibitor.
doi:10.1371/journal.pone.0019329.t002
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PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e19329Figure 1. The effect of vardenafil and tadalafil on the accumulation (A), and efflux (B) of [
3H]-paclitaxel, and ABCB1 expression (C)
in ABCB1 overexpressing cells. (A) The accumulation of [
3H]-paclitaxel was measured after cells were pre-incubated with or without vardenifil,
tadalafil, or verapamil for 1 h at 37uC and then incubated with 0.1 mM[
3H]-paclitaxel for another 2 h at 37uC. (B) The percentage of the paclitaxel
released was plotted as a function of time. After 1 h of incubation of the vardenifil, [
3H]-paclitaxel was co-incubated in KB-3-1 and KB-C2 cells with or
without vardenafil or verapamil. Data points represent the means 6 SD of triplicate determinations. * and ** represent p,0.05 and p,0.01,
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ABCB1
The reversal of ABCB1-mediated MDR could occur by either
decreasing ABCB1 expression or by inhibiting ABCB1 activity. To
determine the effect of vardenafil on ABCB1 expression, the
ABCB1 over-expressing KB-C2 cells were incubated with 10 mM
of vardenafil or tadalafil for 36 h and 72 h. The result of the
Western blot is given in Figure 1C, and it indicates that the protein
level of ABCB1 in KB-C2 cells was not significantly altered after
the cells were incubated with vardenafil (left panel) or tadalafil
(right panel). Because we used whole cell lysates for the Western
blot analysis, it is impossible to determine whether the ABCB1
protein is on membrane or has translocated inside the cell.
Therefore, we performed an immunofluorescence assay to see if
the location of the ABCB1 transporter was altered. The results
suggest neither 10 mM of vardenafil or tadalafil altered the
expression of ABCB1 in the membrane of the KB-C2 cells at least
after 72 h of incubation (data not shown). Overall, these
experiments suggest that neither vardenafil nor tadalafil inhibit
the expression of the ABCB1 transporter and they do not alter the
translocation of ABCB1 in MDR cancer cells.
The effect of vardenafil and tadalafil on the ATPase
activity of ABCB1
The drug efflux function of ABCB1 is coupled to ATP
hydrolysis by the ATPase enzyme that is usually stimulated in
the presence of ABCB1 substrates [28]. To assess the effect of
vardenafil and tadalafil on the ATPase activity of ABCB1, the rate
of ABCB1-mediated ATP hydrolysis was measured in the isolated
membrane vesicles in the presence of various concentrations of
vardenafil or tadalafil under conditions that suppressed the activity
of the other major membrane ATPases. As shown in Figure 2A,
vardenafil produced a concentration-dependent increase in the
ATPase activity of ABCB1 over a range of concentrations. The
concentration of vardenafil required for 50% stimulation of
ATPase activity was 2.69 mM. However, tadalafil only mildly
stimulates ATPase activity, without reaching the concentration
required for 50% stimulation even at highest concentrations used.
Effect of vardenafil and tadalafil on the photoaffinity
labeling of ABCB1 with [
125I]-IAAP
In order to determine if vardenifil interacts with the substrate
binding sites of ABCB1, we measured the effect of vardenafil and
tadalafil on the photoaffinity labeling of the ABCB1 transporter
with [
125I]-IAAP using the membrane vesiclesl. As indicated in
Figure 2B, vardenafil inhibited the photoaffinity labeling of
ABCB1 with [
125I]-IAAP in a concentration-dependent manner.
Vardenafil, at concentrations of 0.69 mM and 10 mM, inhibited
the [
125I]-IAAP photolabeling of ABCB1 by 50% and 90%,
respectively, whereas concentrations of tadalafil up to 50 mM did
not produce a 50% inhibition of the [
125I]-IAAP photolabeling of
the ABCB1 transporter.
Model for binding of vardenafil and tadalafil to ABCB1
In the present study, the PDE5 inhibitors vardenafil and
tadalafil have been described for the first time as ABCB1
inhibitors. Their predicted binding conformation within the large
cavity of ABCB1 is yet to be determined. Additionally, the crystal
structure of the human ABCB1 remains to be elucidated.
Therefore, we sought to develop a homology model of human
ABCB1 based on the mouse ABCB1-QZ59-RRR co-crystal
structure as a template and use the resulting homology model
(Figure 3A) for the Glide docking study of vardenafil and tadalafil.
Four binding sites were reported in the crystal structure of mouse
ABCB1 as represented by the following sites: ABCB1-QZ59-RRR
(site-1), ABCB1-QZ59-SSS (site-2), ABCB1-verapamil (site-3) and
the site common to the above three sites (site-4) [27]. Since the
photoaffinity labeling data suggested that vardenafil displaces
respectively, for values versus those in the control group. (C) Effect of vardenafil (left panel) or tadalafil (right panel) on the expression of ABCB1 for 36
and 72 h, respectively. Independent experiments were performed at least three times, and a representative experiment is shown.
doi:10.1371/journal.pone.0019329.g001
Figure 2. The effect of vardenafil or tadalafil on the ATPase
activity of ABCB1 (A) and the photoaffinity labeling of ABCB1
with [
125I]-IAAP. (B). (A) The Vi-sensitive ATPase activity of ABCB1 in
membrane vesicles was determined with different concentrations of
vardenafil (closed circles) or tadalafil (closed squares) as described
previously [24]. The concentration required for 50% stimulation with
vardenafil was 2.6960.72 mM; whereas the stimulation with tadalafil
was not saturable. (B) The photoaffinity labeling of ABCB1 with [
125I]-
IAAP was performed in the presence or absence of different
concentrations of vardenafil (A) or tadalafil (B). The radioactivity
incorporated into ABCB1 was determined by exposing the gel to an
X-ray film at 270uC. Mean values are given, and the error bars represent
standard error from at least three independent experiments.
doi:10.1371/journal.pone.0019329.g002
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manner, we also docked IAAP to these sites for comparison.
These data also indicated that vardenafil and IAAP share same
binding site i.e., site-1, however, the tadalafil binding site is
somewhat different from QZ59-RRR site i.e., site-4 as predicted
by Glide docking score (Table S1). A comparison of the binding
energy data for the docked poses of vardenafil, tadalafil and IAAP
at each of the binding sites (Table S1) suggested that most potent
ABCB1 inhibitor, vardenafil, exhibited the most favorable binding
energy within the QZ59-RRR binding site of ABCB1, whereas
tadalafil interacted most favorably with site-4. Thus, the following
section will discuss the bound conformation of vardenafil and
tadalafil in site-1 and in site-4, respectively. It should be noted that
the binding energy data for vardenafil and tadalafil (Table S1)
within each of the predicted ABCB1 sites is yet to be
experimentally validated. Although the docking results have not
Figure 3. (A) The ribbon diagram of open to the cytoplasm-3D structural conformation of a homology model of human ABCB1 based on the crystal
structure coordinates of mouse ABCB1. The docked poses of vardenafil (Green), tadalafil (Brown) and IAAP (Purple) as a ball and stick model are
shown within the large hydrophobic cavity of ABCB1 at different inhibitor biding sites. (B) The XP-Glide predicted binding mode of vardenafil (left
panel) and tadalafil (right panel). Important amino acids are depicted as sticks with the atoms colored as carbon – green, hydrogen – white, nitrogen
– blue, oxygen – red and sulfur – yellow) whereas the inhibitor is shown as a ball and stick model with the same color scheme as above except carbon
atoms are represented in orange. The dotted black line indicates hydrogen bonding interaction whereas a dotted red line indicates interacting
distance.
doi:10.1371/journal.pone.0019329.g003
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vardanafil-ABCB1 and tadalafil-ABCB1, in the interim, the
binding model of these ABCB1 inhibitors may serve as a guide
for further lead optimization studies.
The XP-Glide predicted binding mode of vardenafil indicates
the importance of hydrophobic and electrostatic interactions
within the large drug binding cavity of ABCB1 (Figure 3B, left
panel). While the N-ethylpiperazine (D-ring) of vardenafil forms
hydrophobic contacts with Met69, Phe336, Leu339 and Ile340,
the C-ring along with ethoxy substituent enters into favorable
hydrophobic interactions with Phe72, Leu975 and Phe978. The
A-ring, along with its methyl and propyl substituents and the B-
ring, are engaged in hydrophobic interactions with the side chains
of Phe728, Ala729, Phe732 and Val982. In addition, vardenafil
also appeared to form favorable electrostatic interactions with
residues Tyr953 and Tyr307. For example, the sulfonyl oxygen
atom forms a hydrogen bond with the hydroxyl group of Tyr953 (-
SO2—HO-Tyr953), whereas the carbonyl function of the B-ring is
located at a distance of 4.0 A ˚ from the side chain hydroxyl group
of Tyr307.
The XP-Glide predicted binding mode of tadalafil in site-4 of
the large drug binding cavity of ABCB1 is shown in Figure 3B
(right panel). The A and B-rings of the indole moiety bind to the
hydrophobic pocket formed by the side chains of Phe303, Leu304,
Tyr307 and Phe343. Moreover, Phe343 is also has hydrophobic
contacts with the B-, C- and E-rings. Both E- and F-rings of the
benzodioxole moiety are surrounded by the side chains of Phe336,
Leu339, Phe978 and Val982. The carbonyl oxygen atom (close to
E ring) of the D-ring was stabilized by a hydrogen bonding
interaction with the side chain amide group of Gln725 (-CO—
H2NOC-Gln725). The lower efficacy of tadalafil compared to
vardenafil may be due to the orientation of its hydrophobic N-
methyl substituent of D-ring towards the unfavorable polar
backbone of Met986 and Gly989 and the polar side chain amide
group of Gln990.
Discussion
One of the major mechanisms responsible to MDR in cancer
cells is the overexpression of the ABCB1 transporter. [7,8].
However, currently, none of the ABCB1 inhibitors or modulators
have been approved for clinical oncological practice. The present
study demonstrates for the first time that vardenifil, a PDE-5
inhibitor used in the treatment of male erectile dysfunction,
reverses ABCB1-mediated MDR in a concentration-dependent
manner. The magnitude of vardenafil’s reversal is similar to that of
verapamil, an established, non-selective ABCB1 inhibitor. In
addition, it significantly reverses MDR mediated by the ABCB1
transporter in the drug selected cell line KB-C2 to anticancer
substrates such as colchicine and paclitaxel, whereas it had no
effect on the cytotoxicity to cisplatin, a drug that is not an ABCB1
substrate (Table 1). In order to eliminate the possibility of multiple
factors playing a role in drug selected cell lines, we measured the
effect of vincristine and paclitaxel cytotoxicity on ABCB1
transfected HEK293/ABCB1 cells (Table 2). Therefore, vardena-
fil’s effect was specific to ABCB1 overexpressing cells but had no
significant toxic effects on the parental cells when combined with
ABCB1 transporter substrate anticancer drugs. Additionally,
vardenifil did not affect the function of other prominent ABC
transporters such as ABCC1 and ABCG2 (Table S2) that are
widely known to cause MDR. Consistent with the cytotoxicity
data, the drug accumulation results (Figure 1A) indicated that
vardenafil significantly enhances intracellular paclitaxel accumu-
lation by blocking the efflux of [
3H]-paclitaxel in KB-C2 cells that
overexpress ABCB1 (Figure 1A and 2B). This suggests that
vardenafil potentiates the sensitivity of cells to the cytotoxicity of
paclitaxel by inhibiting the drug efflux function of ABCB1, thereby
increasing the intracellular accumulation of the drug. It is possible
that reversal of MDR produced by vardenafil is due to inhibition
of its transport function or decreased expression of the ABCB1
transporter protein. The Western blot and immunofluorescence
analysis in ABCB1 overexpressing cells incubated with vardenafil
or tadalafil indicated that neither drug significantly altered the
membrane expression or translocation of the ABCB1 transporter
from membrane to intracellular organelles in KB-C2 cells
(Figure 1C and data not shown), respectively. These finding are
in agreement with our results indicating that vardenafil inhibits
ABCB1 function rather than its expression.
In the present study, we also investigated the interaction of
vardenafil with the ABCB1 transporter by using the ATPase and
photoaffinity labeling ([
125I]-IAAP) assays. The ATPase activity of
the ABC transporters is stimulated in the presence of transport
substrates. The substrate-stimulated ATPase activity of ABCB1 is
coupled to drug-transport [28]. Since both vardenafil and tadalafil
stimulated ABCB1-mediated ATPase activity (Fig. 2 A), these
drugs, especially vardenafil might be the transport substrate of
ABCB1. The inhibition of IAAP binding by these compounds also
demonstrated their interaction at the drug-binding site of ABCB1.
In transport assays, vardenafil inhibited the efflux of paclitaxel,
which is a substrate of ABCB1 (Fig. 1). We plan to use
radiolabeled vardenafil to test whether this drug is transported
by ABCB1. In addition, it is important to note that some of the
modulators, which are not transported by ABCB1 such as cis-
flupentixol and disulfiram, also stimulate ATPase activity of this
transporter [29,30]. The basis for the stimulation of ATPase
activity of ABCB1 by modulators is not yet well understood.
As mentioned above, vardenafil is a new PDE-5 inhibitor that is
used in the treatment of erectile dysfunction [31]. It competitively
inhibits cGMP hydrolysis by PDE-5, thereby increasing cGMP
accumulation and relaxation of vascular smooth muscle [32]. The
cGMP blocking effect of vardenafil also makes it a promising
therapeutic agent for the treatment of pulmonary arterial
hypertension, as well as certain cardiovascular dysfunction [33].
Recent data suggest that an increased in PDE-5 expression is
linked with the modulation of certain enzymes involved in the
proliferation and antiapoptotic mechanisms observed in multiple
carcinomas. Thus, the inhibition of PDE-5 may have anticancer
effect [34]. For example, Sarfati and colleagues [35] found that
vardenafil could induce the caspase-dependent apoptosis in
chronic lymphocytic leukemia (CLL) cells. This research group
also reported that vardenafil, as well as tadalafil, could reverse
tumor-induced immunosuppression [36]. In addition vardenafil
has been shown to selectively increase the blood-brain tumor
barrier permeability by inhibiting ABCB1, thereby enhancing the
effects of chemotherapeutic drugs in a mouse metastatic brain
tumor model [37,38]. The current study demonstrates for the first
time that vardenafil significantly reverses MDR mediated by the
ABCB1 transporter. We also examined the effect of another PDE-
5 inhibitor, tadalafil, on ABCB1-mediated paclitaxel resistance. In
contrast to vardenafil, tadalafil, produced only mild reversal of
ABCB1 mediated paclitaxel resistance (Table 1 and 2). One
possible explanation for this difference may be related to their
structures as the molecular structure of vardenafil is markedly
different from that of tadalafil (Table S1) [39]. A number of
pharmacophore models for ABCB1 inhibitors have identified
features such as hydrophobic interactions, hydrogen bond
acceptors, aromatic ring center(s) and positive ionizable groups
[40]. Thus, ABCB1 preferentially binds to positively charged,
Reversal of MDR by Vardenafil
PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e19329amphipathic molecules and this suggests the involvement of acidic
residues such as Asp and Glu in drug binding. Although none of
the predicted binding sites of the human ABCB1 transporter have
acidic residues, there are a few acidic residues located in a region
close to the membrane surface and are accessible from within the
drug binding sites. These acidic residues are implicated in
providing selectivity towards cationic amphipathic drug molecules
through ionic interactions during their entry into the drug binding
site of ABCB1. In the present study, vardenafil (the most potent
ABCB1 inhibitor) exhibit all of the pharmacophoric features
(hydrophobic, hydrogen bond acceptor, aromatic ring centers and
positive ionizable groups) for interaction with the ABCB1 binding
sites, whereas tadalafil (the least potent ABCB1 inhibitor) lacks the
positive ionizable group. Although most of the ABCB1 inhibitors
block the function of ABCB1 transporter protein by binding to the
substrate binding sites, there is evidence for the presence of
multiple binding sites [41] and this hinders the development of a
conclusive structure-activity relationship for ABCB1 inhibitors.
Until the co-crystal structure studies are performed for the
vardenafil-ABCB1 complex, the present docking conformation of
vardenafil will serve as a guide for further development of
imidazotriazinone class of ABCB1 inhibitors.
In summary, this is the first study to indicate that the PDE-5
inhibitor, vardenafil, reverses ABCB1-mediated MDR by directly
blocking the drug efflux function of ABCB1 without affecting the
expression of the transporter. Based on the data presented here,
further in vivo studies are warranted to determine if vardenafil can
inhibit the ABCB1 transporter and reverse ABCB1-mediated
MDR in cancer cells.
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Table S1 Binding energies of vardenafil, tadalafil and IAAP
within each of the predicted binding sites of ABCB1.
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represented by bound QZ59-RRR.
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Table S2 The effect of vardenifil and tadalafil on the reversing
ABCG2- and ABCC1-mediated drug resistance. Cell survival was
determined by MTT assay as described in ‘‘Materials and
Methods’’. Data are the means 6 SD of at least three independent
experiments performed in triplicate. The fold-reversal of MDR
(values given in parentheses) was calculated by dividing the IC50
for cells with the anticancer drug in the absence of inhibitor by
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for values versus that obtained in the absence of inhibitor.
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